Antidepressants - Sliding SSRI Revenues Inevitable

The global antidepressant market has seen extraordinary growth over the last decade. However, with few entrants, and a flood of patent expiries by 2009, the dynamics of this $16.9 billion market are set to undergo a major change. As generic competition intensifies, companies need to carefully re-examine their strategies if they wish to protect their market share. 

Scope

In-depth profiles of current market-leading brands, including major event impacting each brand during 2002-2003 

Analysis of potential strategies to help maximize and protect revenues 

Global sales for leading antidepressants in 2001 and 2002, with projections for future performance to 2011 

Report Highlights

Antidepressant sales are expected to decrease by -21.5% to $13.5 billion by 2011. During the forecast period, 2003-11, the market will experience a period of high volatility as revenues are impacted by consecutive patent expiries and limited product launches. 

The serotonergic class dominates the market, accounting for 57.6% of market share in 2002. However, all of the leading brands will suffer patent expiries by 2009. As physicians are encouraged to utilize cheaper generics, brand players must look towards maximizing revenues through product differentiation and innovative lifecycle strategies. 

Wyeth’s noradrenergic, Effexor has positioned itself as a relatively unique product in the antidepressant market. However, with Lilly’s Cymbalta demonstrating a similar mode of action and anticipated to launch in mid 2004, Effexor is expected to undergo its first major challenge to its market position. 

Reasons to Purchase

Assess leading antidepressants and identify key success factors within this sector 

Understand key market drivers and predict the future performance of key compounds 

Benchmark pipeline antidepressants against currently marketed products and assess their future market potential 

February 2004 Pages: 179 

Publisher: Datamonitor CNS Central Nervous System 2004 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_CNS_Central_Nervous_System_2004.html#a598